Merck doubles down on Skyhawk's tech to drug RNA, promising $600M per autoimmune, metabolic target

Merck doubles down on Skyhawk's tech to drug RNA, promising $600M per autoimmune, metabolic target

Source: 
Endpoints
snippet: 

Early collaborations with big-name partners lent Skyhawk Therapeutics both the endorsements and the capital to pursue a small molecule platform for drugging RNA. And they soon wanted more. When Merck signed on to discover candidates against neurodegeneration and cancer last July, Biogen was just expanding the list of neuro targets they want to go after.